Clinical Trials
202 trialsTrial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Institutes of Health Clinical Center (CC)
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
National Institutes of Health Clinical Center (CC)
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Institutes of Health Clinical Center (CC)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
National Institutes of Health Clinical Center (CC)
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
National Cancer Institute (NCI)
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
National Cancer Institute (NCI)
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
National Institutes of Health Clinical Center (CC)
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Magnesium Supplementation in People With XMEN Syndrome
National Institutes of Health Clinical Center (CC)
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
National Cancer Institute (NCI)
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
National Cancer Institute (NCI)
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
National Cancer Institute (NCI)